HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.

Abstract
The maintenance of the antiemetic efficacy of a combined protocol (intravenous methylprednisolone, oral thiethylperazine and oral amitriptyline) during six consecutive courses of adjuvant FAC chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide) was analysed in 107 female breast cancer patients who completed the six planned courses of treatment. A continuous decrease in complete (no vomiting episodes) and major protection rate (0-2 vomiting episodes) was evident during chemotherapy. Complete protection rate decreased from 62.6% in the first course to 48.6% in the sixth (P less than 0.05, chi 2 test). The respective figures for major protection rate were 76.6% and 58% (P less than 0.01, chi 2 test). These data, together with other from the literature, should be taken into consideration when reviewing the overall results of current antiemetic trials, which usually only mention the results obtained in the first course of chemotherapy.
AuthorsM Martin, E Diaz-Rubio, A Casado, S Dominguez, J Sastre
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 28 Issue 2-3 Pg. 430-2 ( 1992) ISSN: 0959-8049 [Print] England
PMID1591058 (Publication Type: Journal Article)
Chemical References
  • Antiemetics
  • Amitriptyline
  • Doxorubicin
  • Thiethylperazine
  • Cyclophosphamide
  • Fluorouracil
  • Methylprednisolone
Topics
  • Adult
  • Aged
  • Amitriptyline (therapeutic use)
  • Antiemetics (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Cyclophosphamide (adverse effects)
  • Doxorubicin (adverse effects)
  • Drug Therapy, Combination
  • Female
  • Fluorouracil (adverse effects)
  • Humans
  • Methylprednisolone (therapeutic use)
  • Middle Aged
  • Nausea (chemically induced, prevention & control)
  • Thiethylperazine (therapeutic use)
  • Vomiting (chemically induced, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: